Vectura Pursues U.S. Partner For Inhaled Respiratory Therapy - A Generic Advair?
This article was originally published in The Pink Sheet Daily
Executive Summary
Vectura could launch a competitor to Advair in 2011 in Europe, while looking for a U.S. partner.
You may also be interested in...
Vectura Likes Risk Proposition Of New U.S. Partnership For Generic Lung Drug
British biotech partners with unnamed multinational pharma to develop VR315, thought by many to be a generic version of GSK's Advair, in the U.S.
Vectura Likes Risk Proposition Of New U.S. Partnership For Generic Lung Drug
British biotech partners with unnamed multinational pharma to develop VR315, thought by many to be a generic version of GSK's Advair, in the U.S.
Teva Has Grand Ambitions In Respiratory Disease, With An Eye On Advair
Teva expects to more than double its respiratory sales to $2.4 billion by 2015, and launch multiple products in the timeframe, including an Advair-like product.